Study using Nexalin's proprietary DIFS™ 15 mA 77.5 Hz treatment platform demonstrated rapid, large- magnitude improvements in anxiety and depression with benefits maintained at 8-week follow-up Results further validate Nexalin's prior clinical data and support the Company's differentiated, non-invasive approach to deep frequency-based neurostimulation No serious adverse events, seizures or manic/hypomanic switches were reported, reinforcing the favorable tolerability profile of Nexalin's technology HOUSTON, ...